LYAR抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: LOVO cell lysate, Primary antibody: P10419(LYAR Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10419(LYAR Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10419(LYAR Antibody) at dilution 1/140. (Original magnification: ×200)    

  
  

LYAR (Ly-1 antibody reactive) is a nucleolar protein first identified through its reactivity with the Ly-1 antibody, originally raised against murine lymphocyte surface antigens. It belongs to the zinc finger protein family, characterized by a C-terminal C2H2-type zinc finger domain, which suggests roles in nucleic acid binding or protein interactions. LYAR is evolutionarily conserved and implicated in ribosome biogenesis, cell proliferation, and embryonic development. Studies reveal its involvement in regulating rRNA processing and ribosome assembly, linking it to cellular growth control.

In cancer research, LYAR is overexpressed in malignancies like neuroblastoma, prostate cancer, and hepatocellular carcinoma, where it promotes tumorigenesis by enhancing cell cycle progression and inhibiting apoptosis. Its oncogenic potential is partly attributed to interactions with MYC, a key regulator of ribosome biosynthesis. Additionally, LYAR plays a role in maintaining pluripotency in embryonic stem cells, modulating transcription factors like OCT4 and NANOG.

LYAR antibodies are widely used as tools to study its expression, localization, and function. They enable detection via techniques such as Western blotting, immunofluorescence, and immunohistochemistry, aiding research into its mechanistic roles in development and disease. Despite progress, LYAR's precise molecular pathways remain partially unresolved, spurring ongoing investigations into its therapeutic potential as a cancer target or regenerative medicine component.